Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Rhea-AI Summary

Vaxart (Nasdaq: VXRT) has announced its participation in the World Vaccine Congress Washington 2025, scheduled for April 23, 2025, in Washington, D.C. Two key executives will deliver presentations at the event:

Dr. James F. Cummings, Chief Medical Officer, will present on 'Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination' at 1:10 p.m. ET in Room 207A.

Dr. Sean Tucker, Founder and Chief Scientific Officer, will discuss 'Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection' at 3:10 p.m. ET in the same room. The company has been a regular presenter at this annual Washington, D.C. event.

News Market Reaction – VXRT

-1.83%

1 alert

-1.83% News Effect

On the day this news was published, VXRT declined 1.83%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C.

Presentation Information:

Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination
Speaker: Dr. James F. Cummings
Date: Wednesday, April 23, 2025
Time: 1:10 p.m. ET
Room: 207A

Title: Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection
Speaker: Dr. Sean Tucker
Date: Wednesday, April 23, 2024
Time: 3:10 p.m. ET
Room: 207A

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact
Vaxart Media and Investor Relations:   
Matt Steinberg     
FINN Partners
IR@vaxart.com
(646) 871-8481

This press release was published by a CLEAR® Verified individual.

FAQ

What presentations will Vaxart (VXRT) give at the World Vaccine Congress 2025?

Vaxart will deliver two presentations on April 23, 2025: one on oral tablet vaccination by Dr. Cummings at 1:10 PM ET, and another on norovirus vaccine immune profiling by Dr. Tucker at 3:10 PM ET.

When and where is Vaxart (VXRT) presenting at the World Vaccine Congress 2025?

Vaxart is presenting on Wednesday, April 23, 2025, in Room 207A at the World Vaccine Congress in Washington, D.C.

What is Vaxart's (VXRT) focus for their oral vaccine presentation at the 2025 Congress?

The presentation focuses on blocking transmission and boosting existing vaccines through oral tablet vaccination technology.

What research will Dr. Sean Tucker present for Vaxart (VXRT) at the 2025 Congress?

Dr. Tucker will present research on immune profiling of an oral norovirus vaccine candidate, discussing correlates of protection for disease and infection.